(Q39298785)

10 September 2017

title

BAI, a novel cyclin-dependent kinase inhibitor induces apoptosis in A549 cells through activation of caspases and inactivation of Akt. (English)

1 reference

10 September 2017

Shin Kim

1

1 reference

10 September 2017

Jinho Lee

2

1 reference

10 September 2017

Byeong-Churl Jang

3

1 reference

10 September 2017

Taeg Kyu Kwon

4

1 reference

10 September 2017

Jong-Wook Park

5

1 reference

10 September 2017

language of work or name

1 reference

1 February 2013

1 reference

Journal of Cellular Biochemistry

10 September 2017

published in

1 reference

10 September 2017

volume

114

1 reference

10 September 2017

issue

2

1 reference

10 September 2017

page(s)

282-293

1 reference

Green tea constituent epigallocatechin-3-gallate and induction of apoptosis and cell cycle arrest in human carcinoma cells

10 September 2017

cites work

1 reference

Tankyrase 1 interacts with Mcl-1 proteins and inhibits their regulation of apoptosis

21 January 2018

1 reference

AZ703, an imidazo[1,2-a]pyridine inhibitor of cyclin-dependent kinases 1 and 2, induces E2F-1-dependent apoptosis enhanced by depletion of cyclin-dependent kinase 9.

21 January 2018

1 reference

The phosphoinositide 3-kinase pathway

21 January 2018

1 reference

Issues and progress with protein kinase inhibitors for cancer treatment

21 January 2018

1 reference

Cellular survival: a play in three Akts

21 January 2018

1 reference

Curcumin [1,7-bis(4-hydroxy-3-methoxyphenyl)-1-6-heptadine-3,5-dione; C21H20O6] sensitizes human prostate cancer cells to tumor necrosis factor-related apoptosis-inducing ligand/Apo2L-induced apoptosis by suppressing nuclear factor-kappaB via inhibi

21 January 2018

1 reference

In vitro and in vivo activity of R547: a potent and selective cyclin-dependent kinase inhibitor currently in phase I clinical trials

21 January 2018

1 reference

Cell cycle regulation and its aberrations in human lung carcinoma

21 January 2018

1 reference

Active cyclin A-CDK2 complex, a possible critical factor for cell proliferation in human primary lung carcinomas

21 January 2018

1 reference

PI3K/Akt signalling pathway and cancer.

21 January 2018

1 reference

A phase 1 study of SNS-032 (formerly BMS-387032), a potent inhibitor of cyclin-dependent kinases 2, 7 and 9 administered as a single oral dose and weekly infusion in patients with metastatic refractory solid tumors

21 January 2018

1 reference

Compound C sensitizes Caki renal cancer cells to TRAIL-induced apoptosis through reactive oxygen species-mediated down-regulation of c-FLIPL and Mcl-1.

21 January 2018

1 reference

Concurrent amplification of cyclin E and CDK2 genes in colorectal carcinomas

21 January 2018

1 reference

Cleavage of poly(ADP-ribose) polymerase by a proteinase with properties like ICE

21 January 2018

1 reference

Synthesis and biological evaluation of 3,5-diaminoindazoles as cyclin-dependent kinase inhibitors

21 January 2018

1 reference

Phase II study of flavopiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically high-risk disease

21 January 2018

1 reference

Inhibition of the phosphatidylinositol 3-kinase/Akt pathway sensitizes MDA-MB468 human breast cancer cells to cerulenin-induced apoptosis.

21 January 2018

1 reference

Extrinsic pathway- and cathepsin-dependent induction of mitochondrial dysfunction are essential for synergistic flavopiridol and vorinostat lethality in breast cancer cells

21 January 2018

1 reference

A Phase II Study of Flavopiridol in Patients With Previously Untreated Advanced Soft Tissue Sarcoma

21 January 2018

1 reference

Discovery and evaluation of dual CDK1 and CDK2 inhibitors

21 January 2018

1 reference

Flavopiridol induces apoptosis in B-cell chronic lymphocytic leukaemia cells through a p38 and ERK MAP kinase-dependent mechanism

21 January 2018

1 reference

Complexities in the development of cyclin-dependent kinase inhibitor drugs

21 January 2018

1 reference

Targeting XIAP for the treatment of malignancy

21 January 2018

1 reference

Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2/1).

21 January 2018

1 reference

Sulforaphane enhances the therapeutic potential of TRAIL in prostate cancer orthotopic model through regulation of apoptosis, metastasis, and angiogenesis

21 January 2018

1 reference

Anticancer activity and differentially expressed genes in head and neck cancer cells treated with a novel cyclin-dependent kinase inhibitor

21 January 2018

1 reference

Role of PI3-kinase in Bcl-X induction and apoptosis inhibition mediated by IL-3 or IGF-1 in Baf-3 cells

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/JCB.24314

1 reference

10 September 2017

1 reference